A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of the Acute Antisuicidal and Antidepressant Effects of Intranasal (R,S)-Ketamine in Severe Unipolar and Bipolar Depression With and Without Comorbid Alcohol Use Disorder

References (43)

1. Cavanagh JTO, Carson AJ, Sharpe M, et al. Psychological autopsy studies of suicide: a systematic review. Psychol Med. 2003;33(3):395–405. PubMed CrossRef
2. Arsenault-Lapierre G, Kim C, Turecki G. Psychiatric diagnoses in 3275 suicides: a meta-analysis. BMC Psychiatry. 2004;4:37. PubMed CrossRef
3. Niciu MJ, Henter ID, Sanacora G, et al. Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity? World J Biol Psychiatry. 2014;15(1):2–16. PubMed CrossRef
4. Cabrera B, Monroy-Jaramillo N, Fries GR, et al. Brain gene expression pattern of subjects with completed suicide and comorbid substance use disorder. Mol Neuropsychiatry. 2019;5(1):60–73. PubMed CrossRef
5. Rong C, Park C, Rosenblat JD, et al. Predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder. Int J Environ Res Publ Health. 2018;15(4):771. CrossRef
6. Comstock SM, Vaidya JG, Niciu MJ. Neurophysiological correlates and differential drug response in subjects with a family history of an alcohol use disorder. Chronic Stress (Thousand Oaks). 2019;3:2470547019865267. PubMed CrossRef
7. Luckenbaugh DA, Ibrahim L, Brutsche N, et al. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord. 2012;14(8):880–887. PubMed CrossRef
8. Kolp E, Friedman HL, Young MS, et al. Ketamine enhanced psychotherapy: preliminary clinical observations on its effectiveness in treating alcoholism. Humanist Psychol. 2006;34(4):399–422. CrossRef
9. Grabski M, McAndrew A, Lawn W, et al. Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry. 2022;179(2):152–162. PubMed CrossRef
10. Dakwar E, Levin F, Hart CL, et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. 2020;177(2):125–133. PubMed CrossRef
11. Pettinati HM, O’Brien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry. 2013;170(1):23–30. PubMed CrossRef
12. Grunze H, Schaefer M, Scherk H, et al. Comorbid bipolar and alcohol use disorder—a therapeutic challenge. Front Psychiatry. 2021;12:660432. PubMed CrossRef
13. Dadiomov D. Dissociating the clinical role and economic value of intranasal esketamine. J Manag Care Spec Pharm. 2020;26(1):20–22. PubMed CrossRef
14. Lapidus KAB, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970–976. PubMed CrossRef
15. Domany Y, McCullumsmith CB. Single, fixed-dose intranasal ketamine for alleviation of acute suicidal ideation. An emergency department, trans-diagnostic approach: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Arch Suicide Res. 2022;26(3):1250–1265. PubMed CrossRef
16. Gálvez V, Li A, Huggins C, et al. Repeated intranasal ketamine for treatment resistant depression – the way to go? Results from a pilot randomised controlled trial. J Psychopharmacol. 2018;32(4):397–407. PubMed CrossRef
17. Hu YD, Xiang YT, Fang JX, et al. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med. 2016;46(3):623–635. PubMed CrossRef
18. Arabzadeh S, Hakkikazazi E, Shahmansouri N, et al. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. J Affect Disord. 2018;235:236–241. PubMed CrossRef
19. Posner K, Brown GK, Stanley B, et al. The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatr. 2011;168(12):1266–1277. PubMed CrossRef
20. Fantino B, Moore N. The self-reported Montgomery–Åsberg Depression Rating Scale is a useful evaluative tool in Major Depressive Disorder. BMC Psychiatr. 2009;9:26. PubMed CrossRef
21. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979;47(2):343–352. PubMed CrossRef
22. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429–435. PubMed CrossRef
23. Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11(1):125–136. PubMed CrossRef
24. Tabachnick BG, Fidell LS. Using Multivariate Statistics. 6th ed. Harper & Row; 2013.
25. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. PubMed CrossRef
26. Ballard ED, Luckenbaugh DA, Richards EM, et al. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. J Psychiatr Res. 2015;68:68–73. PubMed CrossRef
27. Ionescu DF, Fu DJ, Qiu X, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol. 2021;24(1):22–31. PubMed CrossRef
28. Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175(7):620–630. PubMed CrossRef
29. Fu DJ, Ionescu DF, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry. 2020;81(3):19m13191. PubMed CrossRef
30. Canuso CM, Ionescu DF, Li X, et al. Esketamine nasal spray for the rapid reduction of depressive symptoms in major depressive disorder with acute suicidal ideation or behavior. J Clin Psychopharmacol. 2021;41(5):516–524. PubMed CrossRef
31. Alario AA, Niciu MJ. (Es)Ketamine for suicidal ideation and behavior: clinical efficacy. Chronic Stress (Thousand Oaks). 2022;6:24705470221128017. PubMed CrossRef
32. Chen CC, Zhou N, Hu N, et al. Acute effects of intravenous sub-anesthetic doses of ketamine and intranasal inhaled esketamine on suicidal ideation: a systematic review and meta-analysis. Neuropsychiatric Dis Treat. 2023;19:587–599. CrossRef
33. Bonaventura J, Lam S, Carlton M, et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry. 2021;26(11):6704–6722. PubMed CrossRef
34. Portmann S, Kwan HY, Theurillat R, et al. Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro. J Chromatogr A. 2010;1217(51):7942–7948. PubMed CrossRef
35. Geisslinger G, Hering W, Thomann P, et al. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J Anaesth. 1993;70(6):666–671. PubMed CrossRef
36. Yanagihara Y, Ohtani M, Kariya S, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos. 2003;24(1):37–43. PubMed CrossRef
37. Malinovsky JM, Servin F, Cozian A, et al. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br J Anaesth. 1996;77(2):203–207. PubMed CrossRef
38. Large M, Corderoy A, McHugh C. Is suicidal behaviour a stronger predictor of later suicide than suicidal ideation? A systematic review and meta-analysis. Aust N Z J Psychiatry. 2021;55(3):254–267. PubMed CrossRef
39. McHugh CM, Corderoy A, Ryan CJ, et al. Association between suicidal ideation and suicide: meta-analyses of odds ratios, sensitivity, specificity and positive predictive value. BJPsych Open. 2019;5(2):e18. PubMed CrossRef
40. Ballard ED, Zarate CA Jr. The role of dissociation in ketamine’s antidepressant effects. Nat Commun. 2020;11(1):6431. PubMed CrossRef
41. Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399–405. PubMed CrossRef
42. Zarate CA Jr, Brutsche N, Laje G, et al. Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 2012;72(4):331–338. PubMed CrossRef
43. Embree BG, Whitehead PC. Validity and reliability of self-reported drinking behavior: dealing with the problem of response bias. J Stud Alcohol. 2015;54(3):334–344. PubMed CrossRef